Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor
GSK2256098, and capivasertib work in treating patients with meningioma that is growing,
spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098,
capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Brain Science Foundation Genentech, Inc. GlaxoSmithKline National Cancer Institute (NCI)